• Investigational once-daily pill reduces HbA1c in type 1 diabetes, without hypoglycemia

    13 days ago - By Healio

    An investigational once-daily pill added to optimized insulin therapy was shown to reduce HbA1c among adults with type 1 diabetes during a 12-week trial when compared with placebo plus insulin, according to a presenter.
    In announcing findings from the phase 2 Simplici-T1 trial, researchers said the pill, a novel liver-selective glucokinase activator known as TTP399, was associated with a placebo-subtracted HbA1c reduction of 0.32% at 12 weeks when compared with placebo.
    “This may be the first adjunctive therapy that can help people improve their glycemic control without increasing the
    Read more ...